The study underlines the necessity of precise positioning and monitoring of anatomy changes, especially in IMPT which might require adaptation more often. Since OAR doses remained typically below constraints, IMPT plan adaptation will be indicated by target dose degradations.
| INTRODUCTION
Tumor-conformal treatment plans with steep dose gradients are required for radiotherapeutic treatment of advanced head-and-neck cancer (HNC). The target volumes are surrounded by critical normal tissue structures and may comprise some hundred milliliters when including lymph nodes and/or lymphatic pathways. Conformal dose distributions are typically provided by advanced photon therapy techniques like intensity-modulated radiotherapy (IMRT). 1 While intensity-modulated proton therapy (IMPT) can more effectively reduce the dose to healthy tissue [2] [3] [4] [5] and thus allow for further dose escalation, 6 proton beams are prone to range uncertainties if the penetrated tissue changes during therapy. Gradual intratherapy changes in HNC patient anatomy, mainly caused by weight loss, shrinkage of tumor, and shift of close-by structures can be assessed via imaging, e.g. by computed tomography (CT), and are of concern during radiotherapy treatment. 7, 8 The dosimetric consequences of such changes, namely the potential underdose of target volumes and overdose in organs at risk (OARs), have been quantified in detail for IMRT plans. 9, 10 Treatment plan adaptation can be used to prevent severe dose degradation throughout the fractionated treatment course 11 and is related with lower normal tissue complication probabilities. 12 For IMRT treatment, up to two adaptation steps was reported to be sufficient and is logistically feasible. [13] [14] [15] [16] Adaptive IMRT has been shown to be associated with improved locoregional control, 17 especially for advanced tumor stages. 18 Similar detailed clinical data are not available for IMPT treatment.
Just recently, Placidi et al. 19 reported plan adaptations for 12 of 102 HNC patients treated with proton therapy between 2007 and 2014.
Since proton range is sensitive to tissue changes, positioning uncertainties, and interfractional anatomy changes, stronger dose degradations are possible. First dosimetric investigations for direct comparison of photon and proton dose degradation comprise only a small number of five, 20 six, 21 and ten 22 patient datasets.
The presented in-silico study investigates the difference of IMRT and IMPT plans for 31 advanced HNC patients at the time of treatment planning and after 4 weeks of radiochemotherapy by recalculating the plans on kilovoltage control CTs. The control CTs exhibit typical intratherapy changes which can be considered as a combination of day-to-day setup uncertainty and anatomical changes.
| ME TH ODS 2.A | Patient data
A cohort of advanced HNC patients with UICC stage III or higher received PET/CT imaging prior and during definite radiochemotherapy in our clinic. 23 For the presented retrospective planning study, CT images of the PET/CT scans taken before therapy (CT plan ) and after approximately 20 fractions (CT recalc ) were used from 31 patients without intubation and that were scanned both times with thermoplastic head-and-shoulder mask for a sufficiently large region in cranio-caudal direction. Both CTs were acquired with the same protocol and have the same voxel size of either (1.37 9 1.37 9 5) mm 3 or (0.98 9 0.98 9 3) mm 3 . Patient characteristics are summarized in Table 1 . Patients gave their written consent and the local ethics committee approved the study.
Targets and OARs were delineated on CT plan as described earlier. 4 The gross tumor volume (GTV) included the primary tumor and involved lymph nodes. The clinical target volume (CTV) was created by a 5-10 mm isotropic GTV expansion corrected for noninfiltrated bone and air cavities, and a prophylactic volume for elective lymph nodes defined according to Gr egoire et al. 24 was added. The planning target volume (PTV) was defined by CTV margins of 5 mm in cranio-caudal direction and 4 mm in plane with a 3 mm distance to the external contour except for three patients with skin infiltration. A 10 mm build-up bolus was applied for those patients to achieve adequate dose coverage in IMRT plans. The isotropic PTV concept was used for IMRT and IMPT planning for better comparability of dose distributions outside target volumes and same intersection of OARs with PTV. Published guidelines were applied for parotid gland 25 and brachial plexus delineation 26, 27 and internal guidelines for spinal cord, brain stem, and mandible delineation. Artifacts in soft tissue arising from metal implants were contoured and overwritten before dose calculation. Planning risk volumes with 3 mm margin for spinal cord, brain stem, and plexuses were included.
Contours were transferred from CT plan to CT recalc by deformable image registration and adjusted afterward. Workload of contour adjustment was split among two physicians. CTV sizes for both CT scans, and therefore a quantification of anatomical changes, are included in Table 1 . Even though the CTs are taken from photon radiotherapy patients, the study assumes that anatomical changes induced by IMPT and IMRT are similar.
2.B | Dose prescription, treatment planning
All dose values will be stated in Gy and refer either to absolute absorbed photon dose or to absorbed proton dose weighted by a constant relative biological effectiveness of 1. For each patient, an IMRT and an IMPT plan for the full-field series were calculated as described previously. 4 Step-and-shot IMRT plans were optimized using the treatment planning system (TPS) Pin- Gaussian-shaped pencil beams with nominal sigma beam width of 4 mm in air (highest energy, no range shifter). A spot distance of 4 mm and a minimum spot dose of 0.01 MU were used for optimization. Dose grid resolution was 3 9 3 9 3 mm 3 . Only regions inside the external contour were considered for dose optimization and calculation, i.e. everything outside the external contour was overwritten with air density to assess the pure influence of anatomical changes in the recalculation without interference of relative shifts of head pillow, mask mounting, and inhomogeneities of the PET/CT couch.
2.C | Recalculation on CT recalc
The CT recalc images were rigidly registered to the corresponding CT plan utilizing a 6 degrees of freedom (DoF) algorithm (RayStation 
| RESULTS

Exemplary dose distributions from IMRT and IMPT plans on CT plan
and CT recalc are shown in Fig. 2 . Statistics of investigated fraction dose parameters in OARs, targets and healthy tissue are presented in Fig. 3 and Table 2 .
3.A | Initial treatment plans
Planned dose distributions met planning objectives with CTV V 95% > 99% and V 107% < 0.2% and only slight exceedance of OAR constraints in some patients, mainly for IMRT parotids and mandible which were no dose limiting OARs. IMPT plans were superior 
3.B | Changes after 20 fractions
The contoured CTV on CT recalc was on average (37 AE 24) ml (mean AE standard deviation) smaller than on CT plan (Table 1) . PTV size decreased accordingly by about (131 AE 41) ml. Average parotid shrinkage was (4.1 AE 4.5) ml. Mann-Whitney U tests revealed no correlation between target volume changes and the CT matching score which rated the setup accuracy by the bone conformity. This shows that setup errors are not (necessarily) related to the anatomy changes quantified by target shrinkage.
Recalculated IMPT dose distributions were more inhomogeneous (Fig. 2) , which was quantified by hot-and coldspot volumes > 1 ml. 
| DISCUSSION
We analyzed the potential dose degradation due to intra therapy changes for IMPT treatment plans in comparison to IMRT plans.
Using for the first time a quite large cohort of 31 patients allowed for correlation analyses of dose distortion with CT matching, target size and shrinkage. Investigations for smaller numbers of patients (≤ 10) were performed recently 20-22 utilizing 2-7 control CTs. Only one delineated intra therapy CT was available here. However, it was taken after about 4 weeks, a time point that is associated with the largest dose increase in some OARs for IMPT 22 and that was used earlier for adaptation in IMPT HNC treatment with encouraging clinical outcome for less advanced HNC. 33 Similar to previous studies, we found for IMRT that target dose parameters changed significantly but remained mostly within requirements while OAR dose increase was partly critical, e.g. for parotid glands. IMPT OAR dose changes had slightly larger diversity but remained mostly well below constraints since they were already lower in the initial plan. A substantial loss of target coverage, formation of hotspots and loss of homogeneity and conformity was observed for IMPT which is in accordance with M€ uller et al. 20 and G ora et al.
21
. However, Thomson et al. 22 showed no worsening of target doses for IMPT investigating 10 oropharynx cancer patients with similar disease stage as in our cohort. In their study, nodal level IV was excluded from contouring, since it was not covered by their cone-beam CT images, i.e.
shoulders were excluded as well, but shoulder mismatch was found to be a typical issue in our patients. Furthermore, their generated IMPT plans can be considered as more robust since a mixture of single-field and multi-field optimization was applied which was not feasible with our TPS. The robustness of conventional IMPT plans, like ours, is lower since each beam is allowed to treat the complete CTV, which might especially be problematic for the posterior beam and the anterior target portions in the lower neck. Further advanced planning approaches [34] [35] [36] and, in particular, robustness analyses [36] [37] [38] [39] [40] need to be considered for future studies and to be translated into clinical practice. So far, there is no uniform consensus about the ideal IMPT planning strategy for HNC patients and robust optimization cannot be considered as clinical standard yet. Today, several commercial TPSs provide the possibility for IMPT planning but often without (enough) dedicated tools and algorithms to address the proton-specific problems. Our IMPT plans may be inferior compared to the best achievable on the market, but, to the best of our knowledge, they are not unrealistic. Therefore, the results of this study with the clear IMPT dose degradation in the control CT should be understood as an appeal to make any effort to ensure safe and reliable proton therapy delivery.
Although inter-observer variability in contouring might be of concern for our study (two physicians involved), we applied the same Since change of target volumes were not correlated with maintaining of target coverage, homogeneity and conformity even for accurate positioning, those measures are probably not predictable from observed anatomical changes and IMPT dose recalculation is required. Kraan et al. 41 reported correlation between increased CTV V 107% and initial CTV size, which was low in our study containing more advanced HNC, but moderate correlation between PTV size/ shrinkage and formation of hotspots in healthy tissue was found here.
Besides indicating the importance of monitoring anatomic changes and performing plan adaptation, we have shown that reasonable effort is required for exact patient positioning, since loss of target coverage, homogeneity and conformity were significantly worse for less accurate CT matching for proton plans. Shoulder adjustment and verification of head tilt under the mask system is essential; repositioning by couch shift only is insufficient. We believe that the suboptimal CT matching in this study is realistic for current radiotherapy treatment. The standard image guidance for positioning in proton therapy is orthogonal X-ray 42 to the limitation of having only one control CT available. Thus, no conclusions could be drawn for impact of anatomical changes on biological endpoints like normal tissue complication and tumor control probability, and no investigations on optimal adaptation time points could be performed.
| CONCLUSION
IMPT plans provide superior dose distributions in advanced HNC but these are more prone to intra therapy changes. The study underlines that precise positioning and monitoring of anatomy changes are mandatory for reliable IMPT treatment. In consideration of the larger absolute changes, IMPT plans might require adaptation more often than IMRT plans. Since OAR doses remained typically below constraints, indications for adaptive IMPT should rather be derived from target dose degradation.
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